Nigeria Gets New HIV Drug That Works With 2 Shots a Year

Imagine preventing HIV with just two shots a year instead of remembering a daily pill. That's the promise coming to Nigeria starting this year.

The West African nation will receive 179,700 doses of Lenacapavir by 2028, a long-acting injectable drug that represents a major breakthrough in HIV prevention. Nigeria joins eight other countries as early adopters of the medication, which the Global Fund announced Tuesday during a health briefing in Abuja.

The initial rollout targets eight states: Anambra, Ebonyi, Kwara, Akwa Ibom, Cross River, Benue, Rivers, and the Federal Capital Territory. The Global Fund is providing startup support, with Nigeria's government expected to expand access to other states.

Jean-Thomas Noubossi, Senior Fund Portfolio Manager at the Global Fund, called Lenacapavir a game changer for people who struggle with daily medication routines. "It's offering hope for reaching the population that we have not been able to reach because of all these challenges," he explained.

What makes this launch historic is the timing. For the first time since the HIV pandemic began, a new prevention tool is rolling out simultaneously in developing nations and Western countries, not years apart.

Nigeria has made impressive strides in HIV treatment. Health Minister Iziaq Salako shared that 93 percent of people living with HIV know their status, 99 percent of those diagnosed receive treatment, and 95 percent on treatment have achieved viral suppression. But prevention remains crucial.

The country still records 48,000 new HIV infections annually. UNAIDS Country Director Tina Bondu acknowledged the progress while emphasizing the work ahead to reach the goal of zero new infections by 2030.

The Ripple Effect

This launch signals more than just a new medication. Coordinating Minister of Health Muhammad Pate revealed Nigeria has committed $346 million in 2026 for HIV, tuberculosis, malaria, and strategic health investments, with President Bola Tinubu directing the funds into the national budget.

The shift represents Nigeria moving away from donor-dependent healthcare toward a sustainable, domestically funded system. "The only way that will happen is if Nigeria puts its own money where it matters for the health sector," Pate said, noting contributions will come from federal, state, and local governments.

For at-risk individuals, health officials recommend getting tested and seeking preventive medications under medical guidance. Those testing positive should begin treatment immediately at facilities offering antiretroviral therapy.

The rollout of Lenacapavir offers fresh hope that Nigeria can close critical prevention gaps and protect vulnerable populations with a solution that finally fits into real lives.